The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
Open accessAbstract
Therapeutic drug monitoring (TDM) and model‐informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in individual patients with infections. In particular, critically ill patients display altered, highly variable pharmacokinetics and often suffer from infections caused by less susceptible bacteria. Consequently, TDM has been used to individualize dosing in this patient group for many years. More recently, there has been increasing research on the use of MIPD software to streamline the TDM process, which can increase the flexibility and precision of dose individualization but also requires adequate model validation and re‐evaluation of existing workflows. In parallel, new minimally invasive and noninvasive technologies such as microneedle‐based sensors are being developed, which—together with MIPD software—have the potential to revolutionize how patients are dosed with antibiotics. Nonetheless, carefully designed clinical trials to evaluate the benefit of TDM and MIPD approaches are still sparse, but are critically needed to justify the implementation of TDM and MIPD in clinical practice. The present review summarizes the clinical pharmacology of antibiotics, conventional TDM and MIPD approaches, and evidence of the value of TDM/MIPD for aminoglycosides, beta‐lactams, glycopeptides, and linezolid, for which precision dosing approaches have been recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Organization for Standardization (ISO)
Nahler, G. (2009) · Dictionary of Pharmaceutical Medicine · doi:10.1007/978-3-211-89836-9_723 · Cited by 3,677
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Self-citationKontopantelis, E., Doran, T., Springate, D. A., Buchan, I., & Reeves, D. (2015) · BMJ · doi:10.1136/bmj.h2750 · Cited by 1,001
Aminoglycosides: Nephrotoxicity
Mingeot-Leclercq, M.-P., & Tulkens, P. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1003 · Cited by 757
Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
Guilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
The importance of modeling interoccasion variability in population pharmacokinetic analyses
Karlsson, M. O., & Sheiner, L. B. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01113502 · Cited by 485
Blot, S. I., Pea, F., & Lipman, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.006 · Cited by 444
A suggested approach to once‐daily aminoglycoside dosing.
Begg, E., Barclay, M., & Duffull, S. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05719.x · Cited by 420
Experimental and quasi-experimental designs for evaluating guideline implementation strategies
Grimshaw, J. (2000) · Family Practice · doi:10.1093/fampra/17.suppl_1.s11 · Cited by 382
Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380 · cited 1×
“The traditional surrogate PK marker to assure sufficient antibacterial efficacy of aminoglycosides is a Cmax/MIC ratio exceeding 8– 10, which was developed for Q8H or Q12H dosing intervals.(70) As critically ill patients can display altered fluid balance affecting the VD of hydrophilic aminoglycosides, monitoring of C…”
MethodSawchuk, R. J., & Zaske, D. E. (1976) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01086153 · Cited by 361
Neely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., Schumitzky, A., Yamada, W., Jones, B., & Minejima, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02042-17 · Cited by 359
Cefepime-induced neurotoxicity: a systematic review
Payne, L. E., Gagnon, D. J., Riker, R. R., Seder, D. B., Glisic, E. K., Morris, J. G., & Fraser, G. L. (2017) · Critical Care · doi:10.1186/s13054-017-1856-1 · Cited by 345
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Self-citationMIC-based dose adjustment: facts and fables
Mouton, J. W., Muller, A. E., Canton, R., Giske, C. G., Kahlmeter, G., & Turnidge, J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx427 · Cited by 328
Capiau, S., Veenhof, H., Koster, R. A., Bergqvist, Y., Boettcher, M., Halmingh, O., Keevil, B. G., Koch, B. C. P., Linden, R., Pistos, C., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000643 · Cited by 321
Self-citationRayner, C. R., Forrest, A., Meagher, A. K., Birmingham, M. C., & Schentag, J. J. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00007 · Cited by 306
Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure
Le, J., Bradley, J. S., Murray, W., Romanowski, G. L., Tran, T. T., Nguyen, N., Cho, S., Natale, S., Bui, I., Tran, T. M., et al. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318286378e · Cited by 262
Protein Binding: Do We Ever Learn?
Zeitlinger, M. A., Derendorf, H., Mouton, J. W., Cars, O., Craig, W. A., Andes, D., & Theuretzbacher, U. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01433-10 · Cited by 249
Introduction to Drug Pharmacokinetics in the Critically III Patient
Smith, B. S., Yogaratnam, D., Levasseur-Franklin, K. E., Forni, A., & Fong, J. (2012) · Chest · doi:10.1378/chest.11-1396 · Cited by 230
Wong, G., Briscoe, S., Adnan, S., McWhinney, B., Ungerer, J., Lipman, J., & Roberts, J. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00951-13 · Cited by 229
Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric Analysis
Pea, F., Furlanut, M., Cojutti, P., Cristini, F., Zamparini, E., Franceschi, L., & Viale, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00177-10 · Cited by 198
Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis
Ye, Z.-K., Tang, H.-L., & Zhai, S.-D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077169 · Cited by 181
Wong, G., Briscoe, S., McWhinney, B., Ally, M., Ungerer, J., Lipman, J., & Roberts, J. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky314 · Cited by 169
Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study
Huwyler, T., Lenggenhager, L., Abbas, M., Lorenzini, K. I., Hughes, S., Huttner, B. D., Karmime, A., Uçkay, İ., von Dach, E., Lescuyer, P., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.01.005 · Cited by 150
Broeker, A., Nardecchia, M., Klinker, K. P., Derendorf, H., Day, R. O., Marriott, D. J. E., Carland, J. E., STOCKER, S. L., & Wicha, S. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.02.029 · Cited by 144
Self-citationAbdulla, A., Dijkstra, A., Hunfeld, N., Endeman, H., Bahmany, S., Ewoldt, T. M. J., Muller, A. E., van Gelder, T., Gommers, D. A. M. P. J., & Koch, B. C. P. (2020) · Critical Care · doi:10.1186/s13054-020-03272-z · Cited by 143
Self-citationMatthews, I., Kirkpatrick, C. M. J., & Holford, N. H. G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02114.x · Cited by 110
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults
Roberts, D. J., & Hall, R. I. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.799137 · Cited by 109
Tsuji, Y., Holford, N. H. G., Kasai, H., Ogami, C., Heo, Y., Higashi, Y., Mizoguchi, A., To, H., & Yamamoto, Y. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13262 · Cited by 106
Cusumano, J. A., Klinker, K. P., Huttner, A., Luther, M. K., Roberts, J. A., & LaPlante, K. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa128 · Cited by 104
Sime, F. B., Roberts, M. S., Tiong, I. S., Gardner, J. H., Lehman, S., Peake, S., Hahn, U., Warner, M. S., & Roberts, J. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv123 · Cited by 96
Abdulla, A., Ewoldt, T. M. J., Hunfeld, N., Muller, A. E., Rietdijk, W. J. R., Polinder, S., van Gelder, T., Endeman, H., & Koch, B. C. P. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4781-x · Cited by 95
Self-citationKiang, T. K. L., Ranamukhaarachchi, S. A., & Ensom, M. H. H. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040043 · Cited by 94
Uster, D. W., STOCKER, S. L., Carland, J. E., Brett, J., Marriott, D. J. E., Day, R. O., & Wicha, S. G. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2065 · Cited by 93
Self-citationFrymoyer, A. R., Schwenk, H. T., Zorn, Y., Bio, L. L., Moss, J. D., Chasmawala, B., Faulkenberry, J., Goswami, S., Keizer, R. J., & Ghaskari, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00551 · Cited by 87
Augmented Renal Clearance and How to Augment Antibiotic Dosing
Chen, I. H., & Nicolau, D. P. (2020) · Antibiotics · doi:10.3390/antibiotics9070393 · Cited by 83
Vu, D. H., Bolhuis, M. S., Koster, R. A., Greijdanus, B., de Lange, W. C. M., van Altena, R., Brouwers, J. R. B. J., Uges, D. R. A., & Alffenaar, J. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01054-12 · Cited by 82
Self-citationDiagnostic work-up and specific causes of acute kidney injury
Darmon, M., Ostermann, M., Cerdá, J., Dimopoulos, M. A., Forni, L. G., Hoste, E. A. J., Legrand, M. M., Lerolle, N., Rondeau, É., Schneider, A. G., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4799-8 · Cited by 78
Patel, B. M., Paratz, J. D., See, N. C., Müller, M. J., Rudd, M., Paterson, D. L., Briscoe, S., Ungerer, J. P. J., McWhinney, B. C., Lipman, J., et al. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31824981a6 · Cited by 77
Mouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-06 · Cited by 77
Wicha, S. G., Kees, M. G., Solms, A., Minichmayr, I. K., Kratzer, A., & Kloft, C. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.010 · Cited by 76
Self-citationMinichmayr, I. K., Schaeftlein, A., Kuti, J. L., Zeitlinger, M. A., & Kloft, C. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0463-7 · Cited by 68
Self-citationDalton, B., Rajakumar, I., Langevin, A., Ondro, C., Sabuda, D. M., Griener, T. P., Dersch‐Mills, D., & Rennert‐May, E. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.029 · Cited by 68
Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations
Cheng, Y., Wang, C., Li, Z., Pan, Y., Liu, M.-B., & Jiao, Z. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00937-4 · Cited by 68
Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?
Abdul-Aziz, M. H., & Roberts, J. A. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000810 · Cited by 67
Kristoffersson, A., David‐Pierson, P., Parrott, N. J., Kuhlmann, O., Lavé, T., Friberg, L. E., & Nielsen, E. I. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1856-x · Cited by 65
Self-citationA Bayesian Approach to Tracking Patients Having Changing Pharmacokinetic Parameters
Bayard, D. S., & Jelliffe, R. W. (2004) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/b:jopa.0000029490.76908.0c · Cited by 64
Cojutti, P. G., Merelli, M., Bassetti, M., & Pea, F. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz374 · Cited by 62
A molecular and cellular hypothesis for aminoglycoside-induced deafness
Cortopassi, G. A., & Hutchin, T. P. (1994) · Hearing Research · doi:10.1016/0378-5955(94)90040-x · Cited by 62
Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
Takeda, Y., Matsumoto, K., Watanabe, E. M., Kanazawa, N., Fukamizu, T., Shigemi, A., Yokoyama, Y., Ikawa, K., & Morikawa, N. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s96143 · Cited by 60
Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones
Cattaneo, D., Alffenaar, J. C., & Neely, M. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1166204 · Cited by 59
Self-citationHughes, J. H., Tong, D. M. H., Lucas, S. S., Faldasz, J. D., Goswami, S., & Keizer, R. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2088 · Cited by 58
van den Elsen, S. H. J., Oostenbrink, L. M., Heysell, S. K., Hira, D., Touw, D. J., Akkerman, O. W., Bolhuis, M. S., & Alffenaar, J. C. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000462 · Cited by 53
Self-citationHow to design a study to evaluate therapeutic drug monitoring in infectious diseases?
Märtson, A., Sturkenboom, M. G. G., Stojanova, J., Cattaneo, D., Hope, W. W., Marriott, D. J. E., Patanwala, A. E., Peloquin, C. A., Wicha, S. G., van der Werf, T. S., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.008 · Cited by 53
Self-citationNonparametric Methods in Population Pharmacokinetics
Goutelle, S., Woillard, J., Neely, M. N., Yamada, W. M., & Bourguignon, L. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1650 · Cited by 53
Al‐Sulaiti, F. K., Nader, A. M., Saad, M. O., Shaukat, A., Parakadavathu, R., Elzubair, A. G., Al‐Badriyeh, D., Elewa, H. F., & Awaisu, A. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00551-1 · Cited by 47
Yadav, R., Bulitta, J. B., Nation, R. L., & Landersdorfer, C. B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01011-16 · Cited by 46
Impact of Inaccurate Documentation of Sampling and Infusion Time in Model-Informed Precision Dosing
Alihodzic, D., Broeker, A., Baehr, M., Kluge, S., Langebrake, C., & Wicha, S. G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00172 · Cited by 46
Self-citationCunio, C., Uster, D. W., Carland, J. E., Buscher, H., Liu, Z., Brett, J., Stefani, M., Jones, G. R. D., Day, R. O., Wicha, S. G., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.005 · Cited by 45
Self-citationSou, T., Hansen, J. U., Liepinsh, E., Backlund, M., Ercan, O., Grı̄nberga, S., Cao, S., Giachou, P., Petersson, A., Tomczak, M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2104 · Cited by 42
Self-citationBayesian Data Assimilation to Support Informed Decision Making in Individualized Chemotherapy
Maier, C., Hartung, N., de Wiljes, J., Kloft, C., & Huisinga, W. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12492 · Cited by 39
Matzneller, P., Strommer, S., Drucker, C., Petroczi, K., Schoergenhofer, C., Lackner, E., Jilma, B., & Zeitlinger, M. A. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.582 · Cited by 38
Wicha, S. G., Frey, O. R., Roehr, A. C., Pratschke, J., Stockmann, M., Alraish, R., Wuensch, T., & Kaffarnik, M. F. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.023 · Cited by 38
Self-citationBricheux, A., Lenggenhager, L., Hughes, S., Karmime, A., Lescuyer, P., & Huttner, A. C. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.020 · Cited by 38
Kim, S., Kang, C., Huh, K., Cho, S. Y., Chung, D. R., Lee, S., Kim, Y., & Peck, K. R. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03652-6 · Cited by 37
Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure
Shingde, R., Reuter, S. E., Graham, G. G., Carland, J. E., Williams, K. M., Day, R. O., & STOCKER, S. L. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa320 · Cited by 31
Colin, P. J., Jonckheere, S., & Struys, M. M. R. F. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0643-8 · Cited by 28
Gao, Y., Hennig, S., & Barras, M. A. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0707-9 · Cited by 28
Host-response biomarkers for the diagnosis of bacterial respiratory tract infections
Saleh, M. A. A., van de Garde, E. M. W., & van Hasselt, J. G. C. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0682 · Cited by 27
Concise review: Current and emerging biomarkers of nephrotoxicity
Weber, E. J., Himmelfarb, J., & Kelly, E. J. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.03.002 · Cited by 25
Olson, J. A., Hersh, A. L., Sorensen, J., Zobell, J., Anderson, C., & Thorell, E. A. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz036 · Cited by 24
Thorsted, A., Nielsen, E. I., & Friberg, L. E. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106059 · Cited by 24
Self-citationOnce-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Bhatt, J., Jahnke, N., & Smyth, A. R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002009.pub7 · Cited by 23
Srinivas, N. R., & Syed, M. (2016) · Drugs in R&D · doi:10.1007/s40268-015-0117-5 · Cited by 21
Netterberg, I., Karlsson, M. O., Nielsen, E. I., Quartino, A. L., Lindman, H., & Friberg, L. E. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13477 · Cited by 20
Self-citationGuo, T., van Hest, R. M., Zwep, L. B., Roggeveen, L. F., Fleuren, L. M., Bosman, R. J., van der Voort, P. H. J., Girbes, A. R. J., Mathôt, R. A. A., Elbers, P., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02908-7 · Cited by 18
Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization
Deitchman, A. N., Heinrichs, M. T., Khaowroongrueng, V., Jadhav, S. B., & Derendorf, H. (2016) · The AAPS Journal · doi:10.1208/s12248-016-0020-1 · Cited by 15
Seng, J. J. B., Yong, M. H. A., Peh, Z. X., Soong, J. L., & Tan, M. H. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0670-4 · Cited by 14
Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Commentary
Hamberg, A., & Keizer, R. J. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000390 · Cited by 6
Metadata
- Authors
- Wicha, S. G., Märtson, A., Nielsen, E. I., Koch, B. C. P., Friberg, L. E., Alffenaar, J., Minichmayr, I. K., & the International Society of Anti‐Infective Pharmacology (ISAP), T. P. S. G. O. T. E. S. O. C. M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2021-03-16
- Volume
- 109
- Issue
- 4
- Pages
- 928-941
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W3126910175
- Cited by
- 322
- References
- 82
- FWCI
- 22.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
